Aquestive Raises FY23 Total Revenue Guidance From $42M-$46M To $44M-$48M vs $43.37M Est.
Portfolio Pulse from Benzinga Newsdesk
Aquestive Therapeutics has raised its FY23 total revenue guidance from $42M-$46M to $44M-$48M, compared to the estimated $43.37M.
August 07, 2023 | 8:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aquestive's raised revenue guidance for FY23 could potentially lead to a positive impact on its stock price.
Aquestive's raised revenue guidance indicates a positive outlook for the company's financial performance. This could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100